Brought to you by 
Bioverativ agrees to $11.6bn acquisition offer from Sanofi
09 Mar 2018
Executive Summary
Bioverativ Inc. (therapies for hemophilia and other rare blood disorders) agreed to be acquired by Sanofi for $105 per share in cash (a 73% premium), for an enterprise value of $11.6bn.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bioverativ agrees to $11.6bn acquisition offer from Sanofi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice